Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Lanreotide acetate |
| Trade Name | Somatuline Depot |
| Synonyms | Lantreotide depot|AT-1001 |
| Drug Descriptions |
Somatuline Depot (lantreotide acetate) is a somatostatin analog peptide-based drug, which may decrease growth of neuroendocrine tumors (PMID: 27619395, PMID: 25014687). Somatuline Depot (lantreotide acetate) is FDA approved for use in gastroenteropancreatic neuroendocrine tumors (FDA.gov). |
| DrugClasses | |
| CAS Registry Number | 127984-74-1 |
| NCIT ID | C74584 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cabozantinib + Lanreotide acetate | Cabozantinib Lanreotide acetate | 0 | 1 |
| Debio 4126 + Lanreotide acetate | Debio 4126 Lanreotide acetate | 0 | 1 |
| Lanreotide acetate | Lanreotide acetate | 0 | 2 |
| Lanreotide acetate + Lutetium Lu 177 dotatate | Lanreotide acetate Lutetium Lu 177 dotatate | 0 | 1 |
| Lanreotide acetate + Octreotide | Lanreotide acetate Octreotide | 0 | 1 |
| Lanreotide acetate + Pembrolizumab | Lanreotide acetate Pembrolizumab | 0 | 1 |